S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

$12.05
-0.41 (-3.29%)
(As of 04/17/2024 ET)
Today's Range
$12.04
$12.45
50-Day Range
$12.05
$17.29
52-Week Range
$10.87
$83.60
Volume
1.36 million shs
Average Volume
1.37 million shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.13

NovoCure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
158.3% Upside
$31.13 Price Target
Short Interest
Healthy
5.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.57mentions of NovoCure in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$127,161 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.78) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

78th out of 913 stocks

Surgical & Medical Instruments Industry

14th out of 89 stocks

NVCR stock logo

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

NVCR Stock News Headlines

NovoCure (NASDAQ:NVCR) Stock Rating Reaffirmed by Piper Sandler
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
NovoCure (NVCR) Receives a Buy from Wells Fargo
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Why Novocure Stock Is Jumping Today
NovoCure: Sell The METIS-Inspired Rally
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Novocure Shares Rise After Phase 3 METIS Trial Met Primary Endpoint
NVCR Dec 2025 17.500 call
NVCR Jan 2026 20.000 call
NVCR Apr 2024 10.000 put
NVCR Apr 2024 17.500 call
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/17/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,453
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.13
High Stock Price Target
$51.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+158.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-207,040,000.00
Pretax Margin
-37.65%

Debt

Sales & Book Value

Annual Sales
$509.34 million
Book Value
$3.39 per share

Miscellaneous

Free Float
101,021,000
Market Cap
$1.30 billion
Optionable
Optionable
Beta
0.42
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price target for 2024?

9 equities research analysts have issued 12 month target prices for NovoCure's shares. Their NVCR share price targets range from $15.00 to $51.00. On average, they anticipate the company's stock price to reach $31.13 in the next year. This suggests a possible upside of 158.3% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2024?

NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR stock has decreased by 19.3% and is now trading at $12.05.
View the best growth stocks for 2024 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVCR earnings forecast
.

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.08. The medical equipment provider had revenue of $133.80 million for the quarter, compared to the consensus estimate of $133.80 million. NovoCure had a negative trailing twelve-month return on equity of 51.63% and a negative net margin of 40.65%. The company's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.36) earnings per share.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners